Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Category: Oncotarget

Figure 1: Mechanism of action of MTAP along with downstream effects from its loss.

Oncotarget

Oncotarget | MTAP Loss in Metastatic Breast Cancer Patients: Genomic Landscape

March 14, 2023

“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].” Listen to an audio version… read more

Figure 6: Synergistic/antagonistic combinations.

Oncotarget

Oncotarget | Selective Protection of Normal Cells From Chemotherapy, While Killing Drug-Resistant Cancer Cells

March 13, 2023

“Selective protection of normal cells may transform therapy of cancer.” Listen to an audio version of this press release BUFFALO, NY- March 13, 2023 – A new review paper was… read more

Oncotarget

Oncotarget | Mitochondria Engage the Integrated Stress Response to Promote Tumor Growth

March 8, 2023

“Overall, this research proposes a new paradigm on how AR-independent PCa can drive tumor traits by exploiting mitochondrial signaling pathways [...]” Listen to an audio version of this press release… read more

Oncotarget

Oncotarget | HALP Score: Prognostic Ability in Cancers – A Literature Review

March 6, 2023

“In the last several years, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has emerged in the literature as a new prognostic biomarker [...]” Listen to an audio version of this… read more

Oncotarget

Oncotarget | Unveiling the Non-canonical Functions of EZH2 in Prostate Cancer

March 3, 2023

“In summary, both articles by Yi et al. emphasized the significance of non-canonical functions of EZH2 during PCa [prostate cancer] development [...]” Listen to an audio version of this press… read more

Figure 1: Comparison of progression-free survival (A) and overall survival (B) between children (

Oncotarget

Oncotarget | WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

February 27, 2023

“The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” Listen to an audio version of this press release… read more

Oncotarget

Oncotarget | Oncogenic Driver FGFR3-TACC3 Requires 5 Coiled-coil Heptads for Activation and Disulfide Bonds for Stability

February 23, 2023

“Together, this work highlights the need to investigate different breakpoints of fusion proteins, as they may potentially lack the necessary biological activity required for oncogenesis, ultimately leading to misidentification of… read more

Oncotarget

Oncotarget | Extreme Phenotype Approach Identifies Rare ATR Variants as Potential Male Breast Cancer Susceptibility Alleles

February 21, 2023

“Basic functions of ATR classify it in the category of tumor suppressor genes but further studies show that its role is more complex in the context of cancer.” Listen to… read more

Figure 3: Cancer-specific survival curve based on the inflammation-based prognostic index. Abbreviation: ICPI: inflammation based prognostic index.

Oncotarget

Oncotarget | Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

February 14, 2023

“In this study, the ICPI [inflammation-combined prognostic index] was devised as a novel predictive index of prognosis, and its usefulness was clarified.” Listen to an audio version of this press… read more

Figure 4: Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts.

Oncotarget

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

February 9, 2023

“[...] we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” Listen to an audio version of this press release BUFFALO, NY- February 9, 2023 – A new… read more